Search result for 'granules india'

Granules India expands into the peptide therapeutics segment with the acquisition of Swiss CDMO firm Senn Chemicals AG for CHF 20 million (Rs 192 crore). The acquisition is expected to be completed...

Granules India's net profit for the third quarter ended December 31, 2024, declined 6% year-on-year to Rs 118 crore. Revenue from operations also decreased. The company's shares were trading down...

Shares of Standard Glass Lining Technology Ltd listed with a premium of nearly 26% on Monday, rallying on the BSE and NSE. The company's market valuation stood at Rs 3,541.97 crore.

Granules India's shares soared nearly 7% after the company reported a significant increase in net profit for the June quarter. The stock hit a 52-week high on strong earnings.

Granules India's profit after tax soared to Rs 135 crore in the June quarter, driven by strong performance in the formulations segment and North America business.

Krishna Prasad Chigurupati, promoter of Granules India, sold 3.09% stake for Rs 304 crore via open market transaction, reducing his holding to 31.69%.

Granules India's Q4 profit rose 8% to Rs 130 crore, while revenue declined. The company's full-year profit was down 22%. Read more about the financial results and future outlook.

Granules India receives USFDA approval to market Colchicine Capsules (0.6 mg) for gout prevention and treatment. The generic medication is therapeutically equivalent to Hikma International...

Granules India's consolidated profit after tax rose 1% to Rs 126 crore in Q3 FY24, driven by strong US formulations business performance. Revenue also increased slightly.